Sumant Kulkarni
Stock Analyst at Canaccord Genuity
(1.03)
# 3,497
Out of 4,829 analysts
110
Total ratings
25.26%
Success rate
-14.58%
Average return
Main Sectors:
Stocks Rated by Sumant Kulkarni
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NBIX Neurocrine Biosciences | Maintains: Buy | $158 → $160 | $120.43 | +32.86% | 16 | May 6, 2025 | |
| BIIB Biogen | Maintains: Buy | $265 → $220 | $124.40 | +76.85% | 21 | May 2, 2025 | |
| CRVO CervoMed | Maintains: Buy | $12 → $21 | $9.10 | +130.77% | 5 | Mar 18, 2025 | |
| ZVRA Zevra Therapeutics | Maintains: Buy | $23 → $25 | $7.75 | +222.58% | 6 | Mar 13, 2025 | |
| VYGR Voyager Therapeutics | Maintains: Buy | $14 → $12 | $3.35 | +258.21% | 5 | Mar 13, 2025 | |
| CMPS COMPASS Pathways | Maintains: Buy | $23 → $15 | $3.91 | +283.63% | 3 | Feb 28, 2025 | |
| SAGE Sage Therapeutics | Maintains: Hold | $9 → $8 | $6.75 | +18.52% | 5 | Feb 12, 2025 | |
| CYBN Cybin | Maintains: Buy | $86 → $73 | $6.62 | +1,002.72% | 7 | Feb 12, 2025 | |
| BTAI BioXcel Therapeutics | Maintains: Buy | $112 → $80 | $1.48 | +5,305.41% | 7 | Jan 6, 2025 | |
| GHRS GH Research | Maintains: Buy | $31 → $28 | $10.16 | +175.59% | 4 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 | $1.44 | +663.89% | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $86 → $83 | $2.72 | +2,951.47% | 5 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $14 | $6.45 | +117.05% | 1 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $20 | $9.66 | +107.04% | 3 | May 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $26 | $1.55 | +1,577.42% | 2 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $33 | $17.52 | +88.36% | 13 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $101 → $150 | $20.56 | +629.57% | 4 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $17.96 | - | 2 | Jan 31, 2017 |
Neurocrine Biosciences
May 6, 2025
Maintains: Buy
Price Target: $158 → $160
Current: $120.43
Upside: +32.86%
Biogen
May 2, 2025
Maintains: Buy
Price Target: $265 → $220
Current: $124.40
Upside: +76.85%
CervoMed
Mar 18, 2025
Maintains: Buy
Price Target: $12 → $21
Current: $9.10
Upside: +130.77%
Zevra Therapeutics
Mar 13, 2025
Maintains: Buy
Price Target: $23 → $25
Current: $7.75
Upside: +222.58%
Voyager Therapeutics
Mar 13, 2025
Maintains: Buy
Price Target: $14 → $12
Current: $3.35
Upside: +258.21%
COMPASS Pathways
Feb 28, 2025
Maintains: Buy
Price Target: $23 → $15
Current: $3.91
Upside: +283.63%
Sage Therapeutics
Feb 12, 2025
Maintains: Hold
Price Target: $9 → $8
Current: $6.75
Upside: +18.52%
Cybin
Feb 12, 2025
Maintains: Buy
Price Target: $86 → $73
Current: $6.62
Upside: +1,002.72%
BioXcel Therapeutics
Jan 6, 2025
Maintains: Buy
Price Target: $112 → $80
Current: $1.48
Upside: +5,305.41%
GH Research
Nov 18, 2024
Maintains: Buy
Price Target: $31 → $28
Current: $10.16
Upside: +175.59%
Nov 18, 2024
Maintains: Buy
Price Target: $11
Current: $1.44
Upside: +663.89%
Nov 14, 2024
Maintains: Buy
Price Target: $86 → $83
Current: $2.72
Upside: +2,951.47%
Sep 16, 2024
Maintains: Buy
Price Target: $16 → $14
Current: $6.45
Upside: +117.05%
May 7, 2024
Maintains: Buy
Price Target: $21 → $20
Current: $9.66
Upside: +107.04%
Apr 30, 2024
Maintains: Buy
Price Target: $36 → $26
Current: $1.55
Upside: +1,577.42%
Mar 12, 2024
Maintains: Buy
Price Target: $40 → $33
Current: $17.52
Upside: +88.36%
Aug 3, 2021
Maintains: Buy
Price Target: $101 → $150
Current: $20.56
Upside: +629.57%
Jan 31, 2017
Upgrades: Buy
Price Target: n/a
Current: $17.96
Upside: -